Scalper1 News
Generic drug giant Actavis agreed to buy Forest Laboratories for $25 billion in cash and stock Tuesday, making for the biggest deal yet in specialty pharma’s recent consolidation boom. Both stocks jumped on the news. Actavis (ACT) said the combined firm will have about $15 billion in annual sales, rivaling big pharma Bristol-Myers Squibb (BMY). Sales will be roughly split between branded and generic drugs. Actavis will pay $26.04 Scalper1 News
Scalper1 News